# Afatinib and Necitumumab in Patients With EGFR Mutation Positive Advanced or Metastatic Non-small Cell Lung Cancer

> **NCT03054038** · PHASE1 · TERMINATED · sponsor: **Vanderbilt-Ingram Cancer Center** · enrollment: 22 (actual)

## Conditions studied

- Non-Small Cell Lung Carcinoma

## Interventions

- **DRUG:** Afatinib
- **BIOLOGICAL:** Necitumumab
- **OTHER:** Laboratory Biomarker Analysis

## Key facts

- **NCT ID:** NCT03054038
- **Lead sponsor:** Vanderbilt-Ingram Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2017-07-20
- **Primary completion:** 2022-03-23
- **Final completion:** 2022-03-23
- **Target enrollment:** 22 (ACTUAL)
- **Why stopped:** Low accrual
- **Last updated:** 2022-04-14

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03054038

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03054038, "Afatinib and Necitumumab in Patients With EGFR Mutation Positive Advanced or Metastatic Non-small Cell Lung Cancer". Retrieved via AI Analytics 2026-09-07 from https://api.ai-analytics.org/clinical/NCT03054038. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*